In short
Clinical trials are studying INFLUENZA B VIRUS VICTORIA LINEAGE HAEMAGGLUTININ, RECOMBINANT in influenza vaccine research. These studies look at immune response, safety, and how well different vaccine lots or vaccine types compare. The trials include adults 18 years and older, and one large study focuses on adults 50 years and older.
Key points
- Clinical trials investigating INFLUENZA B VIRUS VICTORIA LINEAGE HAEMAGGLUTININ, RECOMBINANT are focused on influenza vaccine research. Two Phase 2 studies in adults 18 years and older look at immune response and safety, while a larger Phase 3 study in adults 50 years and older examines immunogenicity and lot-to-lot consistency. The studies include healthy adults and people with stable health conditions that raise flu risk. Main outcomes include antibody levels, seroconversion, seroprotection, and safety events. Overall, the trials are designed to see how well the vaccine-related interventions stimulate protection against influenza and how safe they are in the studied groups.
Trial overview
The source data describes three interventional studies that included INFLUENZA B VIRUS VICTORIA LINEAGE HAEMAGGLUTININ, RECOMBINANT as part of influenza vaccine research. Two studies were in Phase 2, and one study was in Phase 3. The main condition studied was Influenza, Human, with one larger study also including healthy people and people with stable comorbidities that increase flu complication risk.
Who was studied
One Phase 2 study included adults 18 years of age and older. Another Phase 2 study also included adults 18 years and older. The Phase 3 study focused on adults aged 50 years and older, including both healthy individuals and people with stable comorbidities.
In simple terms, a comorbidity means another health problem that a person already has. The Phase 3 study used this broader group because it wanted to understand vaccine response in older adults, including those at higher risk of flu problems.
What the trials measured
The Phase 2 studies measured the body’s immune response by looking at antibody titer at Day 29, the fold increase from Day 1 to Day 29, seroconversion, and seroprotection. These are blood-based measures that help show whether the study intervention caused the immune system to respond.
The Phase 3 study measured immunogenicity, which means how strongly the vaccine-related intervention triggered an immune response. It compared results across three lots and also compared the study vaccine approach with other influenza vaccine options using geometric mean titers and seroconversion rates.
Trial design and phases
All three studies were interventional, meaning researchers gave study interventions and then measured the results. The two Phase 2 studies were designed to assess immune response and safety in adults 18 years and older. The Phase 3 study was larger and focused on lot-to-lot consistency and noninferiority comparisons in adults 50 years and older.
Noninferiority means the new approach is being tested to see if it is not worse than the comparison approach by more than a set amount. Lot-to-lot consistency means checking whether different production batches give similar immune responses.
Main study comparisons
In the Phase 2 studies, the goal was to evaluate the humoral immune response, which is the part of the immune system that makes antibodies in the blood. The studies also looked at safety and reactogenicity, meaning the expected short-term reactions after the study intervention.
The Phase 3 study first compared three consecutive lots of aQIVc HD in pairs, then compared aQIVc HD against QIVr and aQIV for each vaccine strain. The study used hemagglutination inhibition, or HI assay, which is a lab test used to measure antibodies against flu strains.
The Phase 3 study included the strain INFLUENZA B VIRUS VICTORIA LINEAGE HAEMAGGLUTININ, RECOMBINANT among the four vaccine strains analyzed. It also included comparisons using other influenza strains named in the source data, such as H1N1 and H3N2 components.
Safety endpoints
The Phase 2 studies tracked solicited administration site or systemic events within 7 days, which means expected reactions at the injection site or in the whole body after the study intervention. They also tracked unsolicited adverse events within 28 days, serious adverse events within 6 months, adverse events of special interest within 6 months, medically attended adverse events within 6 months, and laboratory abnormalities at several time points.
These safety measures help researchers see whether the study intervention causes unexpected problems or changes in blood tests. The Phase 3 study summary in the source data focuses mainly on immune response and lot consistency, while the Phase 2 studies give the clearest detailed safety endpoints.